Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.

MLA

Packer, Milton, et al. “Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.” Journal of the American College of Cardiology, vol. 84, no. 20, Nov. 2024, pp. 1979–94. EBSCOhost, https://doi.org/10.1016/j.jacc.2024.07.013.

APA

Packer, M., Ferreira, J. P., Butler, J., Filippatos, G., Januzzi, J. L., Jr, González Maldonado, S., Panova-Noeva, M., Pocock, S. J., Prochaska, J. H., Saadati, M., Sattar, N., Sumin, M., Anker, S. D., & Zannad, F. (2024). Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program. Journal of the American College of Cardiology, 84(20), 1979–1994. https://doi.org/10.1016/j.jacc.2024.07.013

Chicago

Packer, Milton, João Pedro Ferreira, Javed Butler, Gerasimos Filippatos, James L Januzzi Jr, Sandra González Maldonado, Marina Panova-Noeva, et al. 2024. “Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.” Journal of the American College of Cardiology 84 (20): 1979–94. doi:10.1016/j.jacc.2024.07.013.